$8.96
1.70% yesterday
Nasdaq, Dec 31, 10:08 pm CET
ISIN
US4884452065
Symbol
ZVRA

Zevra Therapeutics Stock price

$8.96
+0.62 7.43% 1M
+0.15 1.70% 6M
+0.62 7.43% YTD
+0.62 7.43% 1Y
+4.37 95.21% 3Y
-2.24 20.00% 5Y
-308.80 97.18% 10Y
-170.24 95.00% 20Y
Nasdaq, Closing price Wed, Dec 31 2025
+0.15 1.70%
ISIN
US4884452065
Symbol
ZVRA
Industry

Key metrics

Basic
Market capitalization
$486.4m
Enterprise Value
$348.2m
Net debt
positive
Cash
$199.5m
Shares outstanding
56.2m
Valuation (TTM | estimate)
P/E
14.0 | 6.8
P/S
5.8 | 4.8
EV/Sales
4.1 | 3.4
EV/FCF
negative
P/B
3.7
Financial Health
Equity Ratio
22.3%
Return on Equity
-266.0%
ROCE
-11.9%
ROIC
-42.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$84.4m | $102.3m
EBITDA
$-23.6m | $-74.7m
EBIT
$-29.0m | $-67.2m
Net Income
$35.3m | $73.4m
Free Cash Flow
$-30.2m
Growth (TTM | estimate)
Revenue
240.4% | 333.3%
EBITDA
70.7% | 7.4%
EBIT
66.4% | 22.7%
Net Income
141.6% | 169.6%
Free Cash Flow
56.6%
Margin (TTM | estimate)
Gross
93.9%
EBITDA
-28.0% | -73.0%
EBIT
-34.3%
Net
41.9% | 71.8%
Free Cash Flow
-35.8%
More
EPS
$0.6
FCF per Share
$-0.5
Short interest
12.3%
Employees
59
Rev per Employee
$400.0k
Show more

Is Zevra Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Zevra Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Zevra Therapeutics forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Zevra Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Zevra Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
84 84
240% 240%
100%
- Direct Costs 5.16 5.16
5% 5%
6%
79 79
309% 309%
94%
- Selling and Administrative Expenses 73 73
37% 37%
87%
- Research and Development Expense 18 18
59% 59%
22%
-24 -24
71% 71%
-28%
- Depreciation and Amortization 5.34 5.34
3% 3%
6%
EBIT (Operating Income) EBIT -29 -29
66% 66%
-34%
Net Profit 35 35
142% 142%
42%

In millions USD.

Don't miss a Thing! We will send you all news about Zevra Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Head office United States
Employees 59
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today